Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EndoVascular Technologies suspends trials of vascular grafting system.

This article was originally published in The Gray Sheet

Executive Summary

ENDOVASCULAR TECHNOLOGIES SUSPENDS CLINICAL TRIALS of its EndoVascular Grafting Systems, discontinuing patient enrollment in both a Phase II study of its tube EndoGraft vascular graft implant and a Phase I study of its bifurcated EndoGraft. The company said it has "voluntarily temporarily suspended" the trials following discovery of breaks in the attachment system of the devices.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel